3rd Annual Oncolytic Virotherapy Summit
The Oncolytic Virotherapy Summit will gather the leaders in immuno-oncolytic virus development to discuss the most up-to-date clinical advances alongside novel innovations being made through the genetic modification of viruses.
Map out the route to market focusing on the strategic advancements needed to improve viral manufacturing yield and scale along with the operational and logistical aspects of delivering oncolytic virotherapies to patients in need.
This year's Oncolytic Virotherapy Summit sets the stage for oncolytic viruses to be the combination therapeutic of choice through enhanced tumor microenvironment and immune modulating activity.
Conference Earlybird (Book by 29/09/17): USD 1999
Conference 1 Workshop Earlybird (Book by 29/09/17): USD 2498
Conference 2 Workshop Earlybird (Book by 29/09/17): USD 2997
Workshop only: USD 599
Conference (Standard rate): USD 2799
Conference 1 Workshop (Standard rate): USD 3298
Conference 2 Workshop (Standard rate): USD 3797
Matt Mulvey (Benevir Biopharm), Charles Morris (PsiOxus Therapeutics), Stephen Thorne (Western Oncolytics), Frank Tufaro (DNAtrix), Stephen Russell (Vyriad), Angelica Loskog (Lokon Pharma), Rob Coffin (Replimune), Matt Coffey (Oncolytics Biotech)
Additional details will be posted as soon as they are available.
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine